Skip to main content
. 2021 Nov 15;10(23):e021624. doi: 10.1161/JAHA.121.021624

Table 1.

Clinical Characteristics of the Study Population

Entire study participants (N=1080) P value Abnormal LVGLS participants (n=143) P value
Normal LVGLS (n=937) Abnormal LVGLS (n=143) Without LA and/or RV impairment (n=93) With LA and/or RV impairment (n=50)
Age, y 62±12 65±11 0.007 64±11 67±11 0.067
Male sex, n (%) 498 (53.2) 102 (71.3) <0.001 68 (73.1) 34 (68.0) 0.563
Hypertension, n (%) 302 (32.2) 67 (46.9) <0.001 47 (50.5) 20 (40.0) 0.292
Diabetes, n (%) 88 (9.4) 21 (14.7) 0.072 15 (16.1) 6 (12.0) 0.624
Hypercholesterolemia, n (%) 347 (37.0) 49 (34.3) 0.577 35 (37.6) 14 (28.0) 0.273
Systolic blood pressure, mm Hg 119±15 125±16 <0.001 125±16 127±15 0.514
Diastolic blood pressure, mm Hg 75±10 77±12 0.003 77±13 79±11 0.386
Heart rate, beats/min 71±10 75±11 <0.001 74±11 77±12 0.141
Current smoking, n (%) 87 (9.3) 14 (9.8) 0.877 12 (12.9) 2 (4.0) 0.138
COPD, n (%) 82 (8.8) 20 (14.0) 0.064 15 (16.1) 5 (10.0) 0.449
Body mass index, kg/m2 23.2±3.3 24.5±3.5 <0.001 24.4±3.4 24.6±3.6 0.699
Laboratory parameters
Glucose, mg/dL 99±19 104±21 0.005 105±24 101±16 0.346
Total cholesterol, mg/dL 206±34 204±31 0.346 204±29 202±35 0.696
LDL cholesterol. mg/dL 125±31 124±29 0.776 124±28 124±31 0.918
HDL cholesterol, mg/dL 67±19 59±16 <0.001 59±15 60±18 0.788
Median C‐reactive protein, mg/dL 0.04 (IQR, 0.02–0.09) 0.06 (IQR, 0.03–0.11) 0.002 0.05 (IQR, 0.03–0.11) 0.07 (IQR, 0.04–0.12) 0.209
Median B‐type natriuretic peptide, pg/mL 16.7 (IQR, 9.4–28.4) 15.1 (IQR, 7.9–31.6) 0.447 15.7 (IQR, 7.4–28.7) 14.6 (IQR, 8.9–38.4) 0.549
Elevated B‐type natriuretic peptide level, n (%) 165 (17.6) 33 (23.1) 0.131 18 (19.4) 15 (30.0) 0.211

Values are mean±SD, n (percentage), or median (25th–75th percentile).

COPD indicates chronic obstructive pulmonary disease; HDL, high‐density lipoprotein; IQR, interquartile range; LA, left atrium; LDL, low‐density lipoprotein; LVGLS, left ventricular global longitudinal strain; and RV, right ventricular.